InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Thomas Jefferson University Hospital in Philadelphia, PA. James Harrop, M.D., Professor of Neurological and Orthopedic Surgery, Co-Director at the Delaware Valley Spinal Cord Injury Center, and Principal Investigator at the site, and Josh Heller, M.D., successfully performed the surgery and implantation approximately 22 hours after the injury occurred.

Dr. Harrop said, “The surgery and implantation went smoothly and the patient is recovering well. We are excited to be part of The INSPIRE Study and we look forward to following and communicating the patient’s progress.”

Chief Executive Officer and Chairman Mark Perrin said, “We are pleased to hear that the patient is doing well. We now have 17 patients enrolled and in follow up, and with this patient marking the second enrollment in the last week, we remain enthusiastic about completing INSPIRE enrollment during the third quarter of this year.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.